Centessa Pharmaceuticals plc (NASDAQ:CNTA) Receives Average Recommendation of "Buy" from Brokerages

Centessa Pharmaceuticals plc (NASDAQ:CNTA - Get Free Report) has received a consensus rating of "Buy" from the ten analysts that are presently covering the stock, Marketbeat.com reports. Ten equities research analysts have rated the stock with a buy recommendation. The average 12 month price objective among brokerages that have issued ratings on the stock in the last year is $27.89.

Several research firms recently issued reports on CNTA. Piper Sandler initiated coverage on shares of Centessa Pharmaceuticals in a report on Monday, March 31st. They issued an "overweight" rating and a $38.00 target price on the stock. Wall Street Zen raised Centessa Pharmaceuticals from a "sell" rating to a "hold" rating in a research note on Thursday, May 22nd. Guggenheim reaffirmed a "buy" rating and set a $28.00 target price on shares of Centessa Pharmaceuticals in a research note on Wednesday, March 26th. Needham & Company LLC began coverage on Centessa Pharmaceuticals in a research note on Wednesday. They issued a "buy" rating and a $35.00 price target on the stock. Finally, Oppenheimer began coverage on Centessa Pharmaceuticals in a report on Thursday, May 8th. They set an "outperform" rating and a $6.00 price target on the stock.

Insiders Place Their Bets

In other news, insider David M. Chao sold 7,000 shares of Centessa Pharmaceuticals stock in a transaction dated Monday, March 17th. The stock was sold at an average price of $17.17, for a total value of $120,190.00. Following the completion of the transaction, the insider now owns 225,007 shares of the company's stock, valued at $3,863,370.19. The trade was a 3.02% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Gregory M. Weinhoff sold 10,000 shares of the firm's stock in a transaction dated Tuesday, May 27th. The shares were sold at an average price of $12.82, for a total transaction of $128,200.00. Following the sale, the insider now owns 122,279 shares of the company's stock, valued at approximately $1,567,616.78. This represents a 7.56% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 175,398 shares of company stock worth $2,551,442. 7.09% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of CNTA. GF Fund Management CO. LTD. purchased a new position in Centessa Pharmaceuticals in the 4th quarter worth about $31,000. Caitong International Asset Management Co. Ltd grew its stake in shares of Centessa Pharmaceuticals by 15,209.5% in the first quarter. Caitong International Asset Management Co. Ltd now owns 3,215 shares of the company's stock worth $46,000 after acquiring an additional 3,194 shares during the period. Osterweis Capital Management Inc. purchased a new position in shares of Centessa Pharmaceuticals during the first quarter valued at approximately $47,000. Barclays PLC lifted its position in Centessa Pharmaceuticals by 1,414.9% during the fourth quarter. Barclays PLC now owns 5,302 shares of the company's stock valued at $89,000 after purchasing an additional 4,952 shares during the period. Finally, BNP Paribas Financial Markets bought a new position in Centessa Pharmaceuticals during the fourth quarter valued at approximately $162,000. 82.01% of the stock is owned by institutional investors.

Centessa Pharmaceuticals Price Performance

CNTA stock traded up $0.18 during trading on Tuesday, reaching $12.95. 607,374 shares of the company were exchanged, compared to its average volume of 653,867. The company has a market capitalization of $1.73 billion, a price-to-earnings ratio of -8.46 and a beta of 1.53. The company has a debt-to-equity ratio of 0.15, a current ratio of 21.52 and a quick ratio of 21.52. The company has a 50-day moving average of $12.91 and a two-hundred day moving average of $15.43. Centessa Pharmaceuticals has a twelve month low of $7.75 and a twelve month high of $19.09.

Centessa Pharmaceuticals (NASDAQ:CNTA - Get Free Report) last announced its quarterly earnings results on Monday, May 12th. The company reported ($0.20) EPS for the quarter, beating analysts' consensus estimates of ($0.35) by $0.15. As a group, equities analysts predict that Centessa Pharmaceuticals will post -1.6 earnings per share for the current fiscal year.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.